On October 5, 2022 Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE technology, reported that it will deliver two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022), taking place virtually and in Boston on November 8-12 (Press release, Medikine, OCT 5, 2022, View Source [SID1234621741]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster presentation will highlight preliminary Phase 1 safety, tolerability, and pharmacokinetic/pharmacodynamic data on Medikine’s lead program, MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikine’s innovative platform technology. A second poster will detail preclinical data on MDK-1654, Medikine’s dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINEs.
Details on the poster presentations are as follows:
Title: A Phase 1 Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of MDK-703, an IL-7 Mimetic With Extended Half-life
Abstract #: 625
Presenter: Ron Barrett, PhD, Medikine
Date/Time: Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST
Title: MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the βγc Form of the IL-2/15 Receptor
Abstract #: 1097
Presenter: Angie Park, PhD, Medikine
Date/Time: Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST
Full abstracts will be made available online and will be included in the Journal for ImmunoTherapy of Cancer (JITC) supplement on November 7. Posters will also be available on the Medikine website at www.Medikine.com following the poster presentations.